Skip to content
Free U.S. Standard shipping · Free international Standard shipping over US$150. Free U.S. shipping · International free over US$150.
Take the assessment

Explore HealthspanX

Preclinical mechanistic study

Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

Jun Yoshino, Kathryn F Mills, Myeong Jin Yoon, Shin-Ichiro Imai

Cell Metabolism · 2011 · 14(4):528–536

Original publication PubMed Full text on PMC

Study at a glance

Design
Preclinical mechanistic study using high-fat-diet and age-associated mouse models of metabolic dysfunction
Population or model
Mouse models of diet-induced and age-associated metabolic dysfunction
Sample size
Multiple mouse cohorts; see publication for group sizes by experiment
Intervention
NMN administered to mice in acute and repeated-treatment experiments
Publication type
Preclinical animal study
Evidence class
preclinical-mechanistic
Research area
Metabolic mechanisms
Trial registration
Not applicable.

Study endpoints

  • Tissue NAD+
  • Glucose tolerance
  • Insulin sensitivity
  • Lipid profiles
  • Oxidative-stress and inflammatory gene expression
  • SIRT1-related pathways

Plain-language summary

This foundational mouse study examined whether restoring NAD+ with NMN could affect metabolic dysfunction caused by high-fat diet or aging.

NMN restored NAD+ in metabolic tissues and improved glucose intolerance in the studied mouse models. The authors also reported changes in hepatic insulin sensitivity, lipid profiles and gene-expression pathways related to oxidative stress, inflammation and circadian biology.

These results helped establish the modern NMN research field, but they are animal-model findings and cannot demonstrate treatment or anti-aging effects in people.

Key findings

  • High-fat feeding reduced NAD+ biosynthesis in metabolic organs in the mouse model.
  • NMN restored NAD+ and improved glucose intolerance in diet-induced diabetic mice.
  • NMN improved glucose intolerance and lipid profiles in age-associated diabetic mouse models.
  • Several molecular effects were linked partly to SIRT1-related signaling.

Limitations

  • Mouse study, not a human clinical trial.
  • Disease models do not reproduce the full complexity of human type 2 diabetes or aging.
  • Doses and exposure cannot be directly translated to human supplement use.
  • Mechanistic and metabolic effects do not establish human clinical outcomes.

Funding and transparency

Funding

Supported in part by National Institute on Aging grant AG02150, the Ellison Medical Foundation, and the Longer Life Foundation to Shin-Ichiro Imai; institutional support from the Washington University Nutrition Obesity Research Center (P30DK056341) and Diabetes Research and Training Center (P60DK020579); and support to Jun Yoshino from the Japan Research Foundation for Clinical Pharmacology, Manpei Suzuki Diabetes Foundation, and Kanae Foundation for the Promotion of Medical Science.

Competing interests

Shin-Ichiro Imai served as a scientific advisory board member for Sirtris, a GSK company.

HealthspanX observation

This paper is historically important for NMN biology but should remain clearly separated from human efficacy evidence.

Interpretive weight

Mechanistic context

Foundational mouse study showing NAD restoration and metabolic effects in diet- and age-associated diabetes models; findings are preclinical and cannot establish human efficacy.

This record summarizes a publication; it is not medical advice or a claim that a HealthspanX product reproduces the study's results. Report a correction.

Your cart (0)

Your cart is empty.

Explore Ultra Pure NMN, read the label and choose your pack when you’re ready.

Explore Ultra Pure NMNExplore the journal
HealthspanX

What are you looking for?

Useful starting points